Abstract
Anthracycline and Trastuzumab-Based Therapy in Early Stage Breast Cancer: Do the Data Justify Cardiac Surveillance?
Highlights
Anthracycline-based and trastuzumab-containing regimens make a significant impact on reducing the risk of distant metastases and improving cause-specific and overall survival in early stage breast cancer
Despite anthracyclines being in use for nearly fifty years, there are no evidence-based guidelines for cardiac surveillance in asymptomatic breast cancer survivors
The current guidelines for cardiac monitoring while on trastuzumab therapy were from clinical trials, with empiricism and not data informing the recommendations for cardiac monitoring
Summary
Anthracycline-based and trastuzumab-containing regimens make a significant impact on reducing the risk of distant metastases and improving cause-specific and overall survival in early stage breast cancer. These regimens may cause cardiomyopathy during and after treatment. Conflicting guideline recommendations leave clinicians and women with early breast cancer unsure about what surveillance recommendations are best in asymptomatic women who received limited doses of anthracycline and trastuzumab-based regimens. Reviewed in this commentary is the lack of evidence to support cardiac surveillance in asymptomatic women with breast cancer receiving limited-dose exposure to anthracyclines. J Cardiol and Cardiovasc Sciences (2018) 2(4): 10-14
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
